Public Employees Retirement Association of Colorado decreased its holdings in Mylan NV (NASDAQ:MYL) by 26.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,466 shares of the company’s stock after selling 23,414 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Mylan were worth $1,295,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. First Trust Advisors LP raised its stake in shares of Mylan by 44.9% during the third quarter. First Trust Advisors LP now owns 2,538,981 shares of the company’s stock worth $50,221,000 after acquiring an additional 786,999 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Mylan by 6.8% during the third quarter. Daiwa Securities Group Inc. now owns 24,504 shares of the company’s stock worth $485,000 after acquiring an additional 1,570 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Mylan by 570.7% during the third quarter. Parallel Advisors LLC now owns 2,998 shares of the company’s stock worth $59,000 after acquiring an additional 2,551 shares in the last quarter. Sompo Japan Nipponkoa Asset Management CO. LTD. raised its stake in shares of Mylan by 8.0% during the third quarter. Sompo Japan Nipponkoa Asset Management CO. LTD. now owns 65,240 shares of the company’s stock worth $1,290,000 after acquiring an additional 4,830 shares in the last quarter. Finally, Gabelli Funds LLC raised its stake in shares of Mylan by 89.6% during the third quarter. Gabelli Funds LLC now owns 247,000 shares of the company’s stock worth $4,886,000 after acquiring an additional 116,700 shares in the last quarter. Hedge funds and other institutional investors own 84.19% of the company’s stock.
Shares of NASDAQ MYL traded down $0.26 during mid-day trading on Wednesday, hitting $17.27. The stock had a trading volume of 7,398,900 shares, compared to its average volume of 6,648,093. The company has a debt-to-equity ratio of 1.17, a quick ratio of 0.84 and a current ratio of 1.43. Mylan NV has a 1 year low of $16.63 and a 1 year high of $36.09. The business has a 50 day moving average price of $18.82 and a two-hundred day moving average price of $19.60. The firm has a market cap of $9.09 billion, a P/E ratio of 3.77, a price-to-earnings-growth ratio of 0.95 and a beta of 1.75.
Mylan (NASDAQ:MYL) last issued its earnings results on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.14 by $0.03. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.01 billion. During the same period in the previous year, the firm earned $1.25 earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts predict that Mylan NV will post 4.31 EPS for the current fiscal year.
Several research analysts have commented on the stock. Evercore ISI reissued a “buy” rating on shares of Mylan in a research note on Friday, August 9th. Credit Suisse Group reissued a “buy” rating and set a $34.50 price target on shares of Mylan in a research note on Wednesday, July 31st. Mizuho lifted their price target on shares of Mylan from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Cfra downgraded shares of Mylan from a “hold” rating to a “sell” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley downgraded shares of Mylan from an “overweight” rating to an “equal” rating and decreased their price target for the stock from $25.00 to $18.00 in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the stock. Mylan presently has an average rating of “Hold” and an average price target of $27.97.
In other news, Director Melina E. Higgins bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were bought at an average cost of $17.68 per share, with a total value of $353,600.00. Following the completion of the purchase, the director now directly owns 33,120 shares in the company, valued at $585,561.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.82% of the stock is owned by insiders.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: What is a back-end load?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.